Effect of piperacillin/tazobactam treatment on human bowel microflora.
The effect of piperacillin/tazobactam treatment on the bowel microflora was studied in 20 patients with intra-abdominal infections. The patients were treated with piperacillin 4 g and tazobactam 500 mg administered intravenously every 8 h for four to eight days. Stool specimens were collected before, during and after treatment. Six patients had measurable faecal concentrations of piperacillin (1.2-276 mg/kg) and four patients measurable concentrations of tazobactam (0.8-22.2 mg/kg) during treatment. The mean numbers of enterobacteria, enterococci, bifidobacteria, eubacteria, lactobacilli, clostridia and Gram-positive cocci decreased while the numbers of anaerobic Gram-negative cocci and bacteroides were unaffected. The aerobic and anaerobic microflora returned to normal in all patients after the treatment had stopped.
Nord
C E
CE
Department of Microbiology, Huddinge University Hospital, Sweden.
Brismar
B
B
Kasholm-Tengve
B
B
Tunevall
G
G
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001419:Bacteria / Q000187:drug effects; D004359:Drug Therapy, Combination / Q000493:pharmacokinetics / Q000494:pharmacology; D005243:Feces / Q000737:chemistry / Q000382:microbiology; D005260:Female; D006801:Humans; D007422:Intestines / Q000187:drug effects / Q000382:microbiology*; D008297:Male; D008875:Middle Aged; D010397:Penicillanic Acid / Q000493:pharmacokinetics / Q000494:pharmacology*; D010878:Piperacillin / Q000493:pharmacokinetics / Q000494:pharmacology*; D000078142:Tazobactam; D065093:beta-Lactamase Inhibitors
D065093:beta-Lactamase Inhibitors; D010397:Penicillanic Acid; D000078142:Tazobactam; D010878:Piperacillin